Compare Piramal Healthcare with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PIRAMAL ENTERPRISES vs CIPLA - Comparison Results

PIRAMAL ENTERPRISES     Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PIRAMAL ENTERPRISES CIPLA PIRAMAL ENTERPRISES/
CIPLA
 
P/E (TTM) x 18.4 24.3 75.9% View Chart
P/BV x 1.2 2.5 47.2% View Chart
Dividend Yield % 1.5 0.6 233.8%  

Financials

 PIRAMAL ENTERPRISES   CIPLA
EQUITY SHARE DATA
    PIRAMAL ENTERPRISES
Mar-19
CIPLA
Mar-19
PIRAMAL ENTERPRISES/
CIPLA
5-Yr Chart
Click to enlarge
High Rs3,303678 487.1%   
Low Rs1,797484 371.4%   
Sales per share (Unadj.) Rs716.5198.2 361.4%  
Earnings per share (Unadj.) Rs79.718.5 430.3%  
Cash flow per share (Unadj.) Rs107.935.0 308.4%  
Dividends per share (Unadj.) Rs28.003.00 933.3%  
Dividend yield (eoy) %1.10.5 212.6%  
Book value per share (Unadj.) Rs1,477.5186.3 793.0%  
Shares outstanding (eoy) m184.45805.70 22.9%   
Bonus/Rights/Conversions ISESOP-  
Price / Sales ratio x3.62.9 121.4%   
Avg P/E ratio x32.031.4 102.0%  
P/CF ratio (eoy) x23.616.6 142.3%  
Price / Book Value ratio x1.73.1 55.4%  
Dividend payout %35.116.2 216.9%   
Avg Mkt Cap Rs m470,292468,031 100.5%   
No. of employees `0007.822.6 34.5%   
Total wages/salary Rs m22,50428,565 78.8%   
Avg. sales/employee Rs Th16,899.47,053.1 239.6%   
Avg. wages/employee Rs Th2,877.71,261.5 228.1%   
Avg. net profit/employee Rs Th1,879.9659.1 285.2%   
INCOME DATA
Net Sales Rs m132,153159,710 82.7%  
Other income Rs m3,1284,766 65.6%   
Total revenues Rs m135,281164,475 82.3%   
Gross profit Rs m66,29030,973 214.0%  
Depreciation Rs m5,20213,263 39.2%   
Interest Rs m44,0971,684 2,618.1%   
Profit before tax Rs m20,11920,791 96.8%   
Minority Interest Rs m3,194-172 -1,860.1%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m8,6115,695 151.2%   
Profit after tax Rs m14,70114,924 98.5%  
Gross profit margin %50.219.4 258.7%  
Effective tax rate %42.827.4 156.3%   
Net profit margin %11.19.3 119.0%  
BALANCE SHEET DATA
Current assets Rs m122,742124,266 98.8%   
Current liabilities Rs m310,81037,715 824.1%   
Net working cap to sales %-142.354.2 -262.6%  
Current ratio x0.43.3 12.0%  
Inventory Days Days2391 25.5%  
Debtors Days Days3995 40.9%  
Net fixed assets Rs m116,904105,190 111.1%   
Share capital Rs m3691,611 22.9%   
"Free" reserves Rs m272,161148,511 183.3%   
Net worth Rs m272,530150,123 181.5%   
Long term debt Rs m270,19638,301 705.5%   
Total assets Rs m856,261239,633 357.3%  
Interest coverage x1.513.3 10.9%   
Debt to equity ratio x1.00.3 388.6%  
Sales to assets ratio x0.20.7 23.2%   
Return on assets %6.96.9 99.1%  
Return on equity %5.49.9 54.3%  
Return on capital %12.411.8 104.9%  
Exports to sales %034.7 0.0%   
Imports to sales %00-   
Exports (fob) Rs mNA55,419 0.0%   
Imports (cif) Rs mNANA-   
Fx inflow Rs m15,20057,410 26.5%   
Fx outflow Rs m4,88919,041 25.7%   
Net fx Rs m10,31238,368 26.9%   
CASH FLOW
From Operations Rs m-115,97516,911 -685.8%  
From Investments Rs m-8,265-16,687 49.5%  
From Financial Activity Rs m107,525-3,487 -3,083.4%  
Net Cashflow Rs m-16,650-3,451 482.5%  

Share Holding

Indian Promoters % 52.9 16.0 330.6%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 4.0 12.2 32.8%  
FIIs % 26.6 23.7 112.2%  
ADR/GDR % 0.0 1.1 -  
Free float % 16.5 26.2 63.0%  
Shareholders   93,274 161,166 57.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PIRAMAL ENTERPRISES With:   BIOCON   CADILA HEALTHCARE  VENUS REMEDIES  PLETHICO PHARMA  GLENMARK PHARMA  

Compare PIRAMAL ENTERPRISES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

CIPLA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 9, 2019 | Updated on Sep 9, 2019

Here's an analysis of the annual report of CIPLA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

CIPLA Announces Quarterly Results (1QFY20); Net Profit Up 5.6% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CIPLA has posted a net profit of Rs 5 bn (up 5.6% YoY). Sales on the other hand came in at Rs 40 bn (up 1.3% YoY). Read on for a complete analysis of CIPLA's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY20); Net Profit Up 390.0% (Quarterly Result Update)

Aug 1, 2019 | Updated on Aug 1, 2019

For the quarter ended June 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 4 bn (up 390.0% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

PIRAMAL ENTERPRISES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 9, 2019 | Updated on Jul 9, 2019

Here's an analysis of the annual report of PIRAMAL ENTERPRISES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of PIRAMAL ENTERPRISES. Also includes updates on the valuation of PIRAMAL ENTERPRISES.

CIPLA Announces Quarterly Results (4QFY19); Net Profit Up 144.0% (Quarterly Result Update)

May 24, 2019 | Updated on May 24, 2019

For the quarter ended March 2019, CIPLA has posted a net profit of Rs 4 bn (up 144.0% YoY). Sales on the other hand came in at Rs 44 bn (up 19.1% YoY). Read on for a complete analysis of CIPLA's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PIRAMAL ENTERPRISES SHARE PRICE


Sep 20, 2019 (Close)

TRACK PIRAMAL ENTERPRISES

  • Track your investment in PIRAMAL ENTERPRISES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PIRAMAL ENTERPRISES

PIRAMAL ENTERPRISES 5-YR ANALYSIS

COMPARE PIRAMAL ENTERPRISES WITH

MARKET STATS